(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 February 2007 (08.02.2007)

PCT

(10) International Publication Number
WO 2007/014940 A3

(51) International Patent Classification:
A61K 31/47 (2006.01) *C07D 215/22* (2006.01)
A61P 31/04 (2006.01)

(21) International Application Number:
PCT/EP2006/064856

(22) International Filing Date: 31 July 2006 (31.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05107159.5 3 August 2005 (03.08.2005) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ANDRIES, Koenraad, Jozef, Lodewijk, Marcel** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KOUL, Anil** [IN/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, A Division of Janssen-Cilag, Campus de Maigremont - BP 615, F-27106 Val de Reuil Cedex (FR). **PASQUIER, Elisabeth, Thérèse, Jeanne** [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, A Division of Janssen-Cilag, Campus de Maigremont - BP 615, F-27106 Val de Reuil Cedex (FR). **LANÇOIS, David, Francis, Alain** [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, A Division of Janssen-Cilag, Campus de Maigremont - BP 615, F-27106 Val de Reuil Cedex (FR).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) Title: QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS



(57) Abstract: Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of Formula (Ia) or (Ib), a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof, wherein R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2 or 3; R^2 is hydrogen; alkyl; hydroxy; mercapto; optionally substituted alkyloxy; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted; Ar; Het or a radical of Formula (II); R^3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is zero, 1, 2, 3 or 4; X is a direct bond or CH_2; R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or R^4 and R^5 may be taken together including the N to which they are attached; R^6 is hydrogen or a radical of Formula (III); R^7 is hydrogen, alkyl, Ar or Het; R^8 is hydrogen or alkyl; R^9 is oxo ; or R^8 and R^9 together form the radical -CH=CH-N=.

WO 2007/014940 A3

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

(88) Date of publication of the international search report:
29 March 2007

(48) Date of publication of this corrected version:
5 July 2007

(15) Information about Corrections:
see PCT Gazette No. 27/2007 of 5 July 2007
Previous Correction:
see PCT Gazette No. 20/2007 of 18 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.